Get the Stockscreener App
36.28
0.64%
0.23
After Hours:
36.28
Agios Pharmaceuticals Inc stock is traded at $36.28, with a volume of 778.07K.
It is up +0.64% in the last 24 hours and up +1.94% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
See More
Previous Close:
$36.05
Open:
$35.135
24h Volume:
778.07K
Relative Volume:
0.67
Market Cap:
$2.16B
Revenue:
$66.05M
Net Income/Loss:
$-422.60M
P/E Ratio:
-5.0034
EPS:
-7.251
Net Cash Flow:
$-384.73M
1W Performance:
-6.30%
1M Performance:
+1.94%
6M Performance:
+27.12%
1Y Performance:
-10.55%
1-Day Range:
$35.09
$36.68
1-Week Range:
$35.09
$40.50
52-Week Range:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
36.28 | 2.14B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
473.09 | 119.94B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
651.91 | 68.27B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
924.60 | 53.28B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.75 | 38.91B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
268.74 | 35.65B | 4.29B | 577.22M | 641.34M | 4.2086 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Reiterated | H.C. Wainwright | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development - Sahm
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program - TradingView
H.C. Wainwright lowers Agios Pharma price target to $52 on trial data - Investing.com
Agios Pharmaceuticals (AGIO) Sees 13% Drop Following Trial Resul - GuruFocus
Agios Pharmaceuticals Reports Phase 2 Trial Results for Tebapiva - GuruFocus
Agios Pharmaceuticals (AGIO) Ends Development of Sickle Cell Dru - GuruFocus
AGIO Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Agios scraps sickle cell treatment after trial shows limited benefit - Reuters
Agios Pharma Drops Sickle Cell Disease Drug After Phase 2 Data Disappoint - MedCity News
Agios pares loss after abandoning sickle cell asset tebapivat (AGIO:NASDAQ) - Seeking Alpha
Agios scraps sickle cell drug - BioPharma Dive
Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move - Investor's Business Daily
Trial miss for Agios Pharma’s tebapivat in sickle cell disease - The Pharma Letter
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset - BioSpace
Agios Shelves Tebapivat In Sickle Cell, Weeks After MDS Exit - insights.citeline.com
Why Is AGIO Stock Falling Today? - Yahoo Finance
Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO) - Yahoo Finance
Agios halts tebapivat development in sickle cell disease - Investing.com
Agios Pharmaceuticals stock falls on trial update By Investing.com - Investing.com South Africa
Agios Pharmaceuticals stock falls on trial update - Investing.com India
Agios Pharmaceuticals Reports Phase 2 Tebapivat Sickle Cell Disease Results, Discontinues Development of the Candidate - Quiver Quantitative
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease - The Manila Times
Agios halts tebapivat development in sickle cell disease By Investing.com - Investing.com UK
Tebapivat 5 mg Arm: 47.1% Hemoglobin Response; Agios Won’t Advance - Stock Titan
The Bull Case For Agios Pharmaceuticals (AGIO) Could Change Following FDA Priority Review For Mitapivat In Sickle Cell - simplywall.st
Agios gains FDA priority review for Pyrukynd label expansion - MSN
The Technical Signals Behind (AGIO) That Institutions Follow - Stock Traders Daily
Agios Pharmaceuticals (AGIO) Wins Priority Review, Is The Stock Now Fully Valued? - Sahm
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia - AOL.com
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $54 - Moomoo
AGIO 260717 45.00P (AGIO260717P45000) Latest Announcements - Moomoo
Agios Pharmaceuticals (NASDAQ: AGIO) director reports 1,447-share equity award and 2,894 RSUs - Stock Titan
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week - AOL.com
Is Agios Pharmaceuticals (AGIO) A Bargain After FDA Priority Review For Mitapivat? - Yahoo Finance
Agios Pharmaceuticals (AGIO) Is Up 13.8% After FDA Grants Priority Review To Mitapivat In Sickle Cell Disease - Yahoo Finance
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up - The Globe and Mail
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? - Yahoo Finance
Why Is Agios Pharma Stock Soaring Tuesday? - Sahm
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $41 to $54 - Moomoo
Eli Lilly Stock Forecast: Why Foundayo Access Could Push LLY Past $1,000 by Late 2026 - finance.biggo.com
What Is Driving Focus on Agios Pharmaceuticals (NASDAQ:AGIO)? - Kalkine Media
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $41 - Moomoo
AGIO Stock Jumps As Mitapivat Trial Data Fuels Bullish Targets - timothysykes.com
After receiving priority review designation from the FDA for its sickle cell disease treatment, Agios Pharmaceuticals, Inc. shares surged by 12.4%. - Bitget
Agios Pharmaceuticals (NASDAQ:AGIO) pops as FDA review moves price above average target - TechStock²
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related) - The Motley Fool
AGIO Maintained by RBC Capital -- Price Target Raised to $32 - GuruFocus
Agios Pharmaceuticals (AGIO) Receives Priority Review from FDA f - GuruFocus
Agios Pharmaceuticals (AGIO) Sees 13.5% Surge - GuruFocus
AGIO Stock Jumps As Mitapivat Sickle Cell Data Fuels Hype - StocksToTrade
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer |
Jul 01 '26 |
Sale |
37.56 |
4,007 |
150,503 |
84,645 |
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):